Literature DB >> 10817751

Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice.

X X Bin1, K Wolf, T Schaffner, R Malinverni.   

Abstract

The effects of treatment with azithromycin plus rifampin (A+R), amoxicillin (A), or placebo (P) on the chronic course of experimental Chlamydia pneumoniae pneumonitis in mice were assessed by culture, PCR, and immunocytochemistry as well as by degree of inflammation in lung tissue. Eradication of the pathogen was significantly more frequent and inflammation in tissue was significantly reduced after treatment with A+R compared to after treatment with A or P. Combination therapy with azithromycin plus rifampin showed favorable effects in the chronic course of C. pneumoniae pneumonitis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10817751      PMCID: PMC89955          DOI: 10.1128/AAC.44.6.1761-1764.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group.

Authors:  E Gurfinkel; G Bozovich; A Daroca; E Beck; B Mautner
Journal:  Lancet       Date:  1997-08-09       Impact factor: 79.321

2.  Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study.

Authors:  J L Anderson; J B Muhlestein; J Carlquist; A Allen; S Trehan; C Nielson; S Hall; J Brady; M Egger; B Horne; T Lim
Journal:  Circulation       Date:  1999-03-30       Impact factor: 29.690

Review 3.  Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae.

Authors:  M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

4.  Protective effects of sparfloxacin in experimental pneumonia caused by Chlamydia pneumoniae in leukopenic mice.

Authors:  K Nakata; Y Okazaki; H Hattori; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

5.  Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction.

Authors:  S Gupta; E W Leatham; D Carrington; M A Mendall; J C Kaski; A J Camm
Journal:  Circulation       Date:  1997-07-15       Impact factor: 29.690

Review 6.  Chlamydia pneumoniae (TWAR).

Authors:  C C Kuo; L A Jackson; L A Campbell; J T Grayston
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

7.  The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor.

Authors:  C Calleja; J M Pascussi; J C Mani; P Maurel; M J Vilarem
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

8.  Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis.

Authors:  R Malinverni; C C Kuo; L A Campbell; A Lee; J T Grayston
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

9.  Relevance of Chlamydia pneumoniae murine pneumonitis model to evaluation of antimicrobial agents.

Authors:  N D Masson; C D Toseland; A S Beale
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

10.  Reactivation of Chlamydia pneumoniae lung infection in mice by cortisone.

Authors:  R Malinverni; C C Kuo; L A Campbell; J T Grayston
Journal:  J Infect Dis       Date:  1995-08       Impact factor: 5.226

View more
  5 in total

1.  Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  Ana María Ríos; Mónica Fonseca-Aten; Asunción Mejías; Susana Chávez-Bueno; Kathy Katz; Ana María Gómez; George H McCracken; Octavio Ramilo; R Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice.

Authors:  Liisa Törmäkangas; Hannu Alakärppä; Denise Bem David; Maija Leinonen; Pekka Saikku
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 3.  Causality of Chlamydiae in Arthritis and Spondyloarthritis: a Plea for Increased Translational Research.

Authors:  Henning Zeidler; Alan P Hudson
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

4.  Chlamydia muridarum enters a viable but non-infectious state in amoxicillin-treated BALB/c mice.

Authors:  R Phillips Campbell; J Kintner; J Whittimore; R V Schoborg
Journal:  Microbes Infect       Date:  2012-08-23       Impact factor: 2.700

Review 5.  Macrolide therapy in chronic inflammatory diseases.

Authors:  Brygida Kwiatkowska; Maria Maślińska
Journal:  Mediators Inflamm       Date:  2012-08-21       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.